[
1. C. Nüsslein-Volhard and E. Wieschaus, Mutations affecting segment number and polarity in Drosophila, Nature 287 (1980) 795–801; https://doi.org/10.1038/287795a010.1038/287795a0
]Search in Google Scholar
[
2. R. Machold, S. Hayashi, M. Rutlin, M. D. Muzumdar, S. Nery, J. G. Corbin, A. Gritli-Linde, T. Dellovade, J. A. Porter, L. L. Rubin, H. Dudek, A. P. McMahon and G. Fishell, Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches, Neuron 39 (2003) 937–950; https://doi.org/10.1016/s0896-6273(03)00561-010.1016/S0896-6273(03)00561-0
]Search in Google Scholar
[
3. C. Torroja, N. Gorfinkiel and I. Guerrero, Mechanisms of Hedgehog gradient formation and interpretation, J. Neurobiol. 64 (2005) 334–356; https://doi.org/10.1002/neu.2016810.1002/neu.2016816041759
]Search in Google Scholar
[
4. M. Varjosalo and J. Taipale, Hedgehog: functions and mechanisms, Genes Dev. 22 (2008) 2454–2472; https://doi.org/10.1101/gad.169360810.1101/gad.169360818794343
]Search in Google Scholar
[
5. E. Pak and R. A. Segal, Hedgehog signal transduction: Key players, oncogenic drivers, and cancer therapy, Dev. Cell 38 (2016) 333–344; https://doi.org/10.1016/j.devcel.2016.07.02610.1016/j.devcel.2016.07.026501730727554855
]Search in Google Scholar
[
6. D. M. Stone, M. Hynes, M. Armanini, T. A. Swanson, Q. Gu, R. L. Johnson, M. P. Scott, D. Pennica, A. Goddard, H. Phillips, M. Noll, J. E. Hooper, F. de Sauvage and A. Rosenthal, The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog, Nature 384 (1996) 129–134; https://doi.org/10.1038/384129a010.1038/384129a08906787
]Search in Google Scholar
[
7. M. Kasper, H. Schnidar, G. W. Neill, M. Hanneder, S. Klingler, L. Blaas, C. Schmid, C. Hauser-Kronberger, G. Regl, M. P. Philpott and F. Aberger, Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes, Mol. Cell. Biol. 26 (2006) 6283–6298; https://doi.org/10.1128/MCB.02317-0510.1128/MCB.02317-05159281616880536
]Search in Google Scholar
[
8. I. D. Louro, E. C. Bailey, X. Li, L. S. South, P. R. McKie-Bell, B. K. Yoder, C. C. Huang, M. R. Johnson, A. E. Hill, R. L. Johnson and J. M. Ruppert, Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation, Cancer Res. 62 (2002) 5867–5873.
]Search in Google Scholar
[
9. L. E. C. Wanshura, K. E. Galvin, H. Ye, M. E. Fernandez-Zapico and C. Wetmore, Sequential activation of Snail1 and N-Myc modulates Sonic Hedgehog-induced transformation of neural cells, Cancer Res. 71 (2011) 5336–5345; https://doi.org/10.1158/0008-5472.CAN-10-263310.1158/0008-5472.CAN-10-2633341268921646478
]Search in Google Scholar
[
10. M. Merchant, F. F. Vajdos, M. Ultsch, H. R. Maun, U. Wendt, J. Cannon, W. Desmarais, R. A. Lazarus, A. M. de Vos and F. J. de Sauvage, Suppressor of Fused regulates Gli activity through a dual binding mechanism, Mol. Cell. Biol. 24 (2004) 8627–8641; https://doi.org/10.1128/MCB.24.19.8627-8641.200410.1128/MCB.24.19.8627-8641.200451676315367681
]Search in Google Scholar
[
11. A. M. Skoda, D. Simovic, V. Karin, V. Kardum, S. Vranic and L. Serman, The role of the Hedgehog signaling pathway in cancer: A comprehensive review, Bosn. J. Basic Med. Sci. 18 (2018) 8–20; https://doi.org/10.17305/bjbms.2018.275610.17305/bjbms.2018.2756582667829274272
]Search in Google Scholar
[
12. C. Zhao, A. Chen, C. H. Jamieson, M. Fereshteh, A. Abrahamsson, J. Blum, H. Y. Kwon, J. Kim, J. P. Chute, D. Rizzieri, M. Munchhof, T. VanArsdale, P. A. Beachy and T. Reya, Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia, Nature 458 (2009) 776–779; https://doi.org/10.1038/nature0773710.1038/nature07737294623119169242
]Search in Google Scholar
[
13. N. Bhagwat, M. D. Keller, R. K. Rampal, K. Shank, E. de Stanchina, K. Rose, D. Amakye and R. L. Levine, Improved efficacy of combination of JAK2 and Hedgehog inhibitors in myelofibrosis, Blood 122 (2013) 666–666; https://doi.org/10.1182/blood.V122.21.666.66610.1182/blood.V122.21.666.666
]Search in Google Scholar
[
14. J. M. Xavier-Ferrucio, F. V. Pericole, M. R. Lopes, P. Latuf-Filho, K. S. A. Barcellos, A. I. Dias, P. de M. Campos, F. Traina, J. Vassallo, S. T. O. Saad and P. Favaro, Abnormal Hedgehog pathway in myelodysplastic syndrome and its impact on patients’ outcome, Haematologica 100 (2015) e491-493; https://doi.org/10.3324/haematol.2015.12404010.3324/haematol.2015.124040466633826294731
]Search in Google Scholar
[
15. M. Kobune, R. Takimoto, K. Murase, S. Iyama, T. Sato, S. Kikuchi, Y. Kawano, K. Miyanishi, Y. Sato, Y. Niitsu and J. Kato, Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells, Cancer Sci. 100 (2009) 948–955; https://doi.org/10.1111/j.1349-7006.2009.01111.x10.1111/j.1349-7006.2009.01111.x19245435
]Search in Google Scholar
[
16. B. Long, L.-X. Wang, F.-M. Zheng, S.-P. Lai, D.-R. Xu, Y. Hu, D.-J. Lin, X.-Z. Zhang, L. Dong, Z.-J. Long, X.-Z. Tong and Q. Liu, Targeting GLI1 suppresses cell growth and enhances chemosensitivity in CD34+ enriched acute myeloid leukemia progenitor cells, Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 38 (2016) 1288–1302; https://doi.org/10.1159/00044307510.1159/00044307527008269
]Search in Google Scholar
[
17. K. C. S. Queiroz, R. R. Ruela-de-Sousa, G. M. Fuhler, H. L. Aberson, C. V. Ferreira, M. P. Peppelen-bosch and C. A. Spek, Hedgehog signaling maintains chemoresistance in myeloid leukemic cells, Oncogene 29 (2010) 6314–6322; https://doi.org/10.1038/onc.2010.37510.1038/onc.2010.37520802532
]Search in Google Scholar
[
18. H. A. Zahreddine, B. Culjkovic-Kraljacic, S. Assouline, P. Gendron, A. A. Romeo, S. J. Morris, G. Cormack, J. B. Jaquith, L. Cerchietti, E. Cocolakis, A. Amri, J. Bergeron, B. Leber, M. W. Becker, S. Pei, C. T. Jordan, W. H. Miller and K. L. B. Borden, The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation, Nature 511 (2014) 90–93; https://doi.org/10.1038/nature1328310.1038/nature13283413805324870236
]Search in Google Scholar
[
19. K. Huang, B. Ding, Q. Zhong, X. Jiang, X. Li, Z. Wang and F. Y. Meng, Hh/IGF-1R/PI3K/Akt/MRP1 pathway induce refractory acute myeloid leukemia and its targeting therapy, Blood 124 (2014) 3612–3612; https://doi.org/10.1182/blood.V124.21.3612.361210.1182/blood.V124.21.3612.3612
]Search in Google Scholar
[
20. F. Meng, X. Li, B. Ding, K. Huang, Q. Zhu, F. Chen and Y. Zhu, Molecular mechanism and optimal treatment strategy in acute myeloid leukemia with resistance to drugs and radiation by NVPLED225, Blood 126 (2015) 3691–3691; https://doi.org/10.1182/blood.V126.23.3691.369110.1182/blood.V126.23.3691.3691
]Search in Google Scholar
[
21. X. Li, F. Chen, Q. Zhu, B. Ding, Q. Zhong, K. Huang, X. Jiang, Z. Wang, C. Yin, Y. Zhu, Z. Li and F. Meng, Gli-1/PI3K/AKT/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells, Oncotarget 7 (2016) 33004–33015; https://doi.org/10.18632/oncotarget.884410.18632/oncotarget.8844507807027105509
]Search in Google Scholar
[
22. J. Bariwal, V. Kumar, Y. Dong and R. I. Mahato, Design of Hedgehog pathway inhibitors for cancer treatment, Med. Res. Rev. 39 (2019) 1137–1204; https://doi.org/10.1002/med.2155510.1002/med.21555671458530484872
]Search in Google Scholar
[
23. R. Tibes, A. Al-Kali, G. R. Oliver, D. H. Delman, N. Hansen, K. Bhagavatula, J. Mohan, F. Rakhshan, T. Wood, J. M. Foran, R. A. Mesa and J. M. Bogenberger, The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia, J. Hematol. Oncol. 8 (2015) 114; https://doi.org/10.1186/s13045-015-0211-810.1186/s13045-015-0211-8461536326483188
]Search in Google Scholar
[
24. D. A. Irvine, B. Zhang, R. Kinstrie, A. Tarafdar, H. Morrison, V. L. Campbell, H. A. Moka, Y. Ho, C. Nixon, P. W. Manley, H. Wheadon, J. R. Goodlad, T. L. Holyoake, R. Bhatia and M. Copland, Deregulated Hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia, Sci. Rep. 6 (2016) 25476; https://doi.org/10.1038/srep2547610.1038/srep25476486061927157927
]Search in Google Scholar
[
25. J. E. Cortes, R. Gutzmer, M. W. Kieran and J. A. Solomon, Hedgehog signaling inhibitors in solid and hematological cancers, Cancer Treat. Rev. 76 (2019) 41–50; https://doi.org/10.1016/j.ctrv.2019.04.00510.1016/j.ctrv.2019.04.00531125907
]Search in Google Scholar
[
26. J. E. Cortes, F. H. Heidel, A. Hellmann, W. Fiedler, B. D. Smith, T. Robak, P. Montesinos, D. A. Pollyea, P. DesJardins, O. Ottmann, W. W. Ma, M. N. Shaik, A. D. Laird, M. Zeremski, A. O’Connell, G. Chan and M. Heuser, Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome, Leukemia 33 (2019) 379–389; https://doi.org/10.1038/s41375-018-0312-910.1038/s41375-018-0312-9636549230555165
]Search in Google Scholar
[
27. S. M. Hoy, Glasdegib: First global approval, Drugs 79 (2019) 207–213; https://doi.org/10.1007/s40265-018-1047-710.1007/s40265-018-1047-730666593
]Search in Google Scholar
[
28. K. J. Norsworthy, K. By, S. Subramaniam, L. Zhuang, P. L. Del Valle, D. Przepiorka, Y.-L. Shen, C. M. Sheth, C. Liu, R. Leong, K. B. Goldberg, A. T. Farrell and R. Pazdur, FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia, Clin. Cancer Res. 25 (2019) 6021–6025; https://doi.org/10.1158/1078-0432.CCR-19-036510.1158/1078-0432.CCR-19-036531064779
]Search in Google Scholar
[
29. E. Estey, J. E. Karp, A. Emadi, M. Othus and R. P. Gale, Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?, Leukemia 34 (2020) 671–681; https://doi.org/10.1038/s41375-019-0704-510.1038/s41375-019-0704-531915366
]Search in Google Scholar
[
30. T. Hilal, Progress in acute myeloid leukaemia: small molecular inhibitors with small benefits, Ecancermedicalscience 14 (2020); https://doi.org/10.3332/ecancer.2020.101510.3332/ecancer.2020.1015710534032256698
]Search in Google Scholar
[
31. A. Fiorentini, D. Capelli, F. Saraceni, D. Menotti, A. Poloni and A. Olivieri, The time has come for targeted therapies for AML: lights and shadows, Oncol. Ther. 8 (2020) 13–32; https://doi.org/10.1007/s40487-019-00108-x10.1007/s40487-019-00108-x735999632700072
]Search in Google Scholar
[
32. M. J. Munchhof, Q. Li, A. Shavnya, G. V. Borzillo, T. L. Boyden, C. S. Jones, S. D. LaGreca, L. Martinez-Alsina, N. Patel, K. Pelletier, L. A. Reiter, M. D. Robbins and G. T. Tkalcevic, Discovery of PF-04449913, a potent and orally bioavailable inhibitor of Smoothened, ACS Med. Chem. Lett. 3 (2012) 106–111; https://doi.org/10.1021/ml200242310.1021/ml2002423
]Search in Google Scholar
[
33. L. Rubin, O. M. Guicherit, S. Price and E. A. Boyd, Mediators of Hedgehog signaling pathways, compositions and uses related thereto; Retrieved from https://patents.google.com/patent/WO2003011219A2/en
]Search in Google Scholar
[
34. A. J. Jackson-Fisher, M. J. McMahon, J. Lam, C. Li, L. D. Engstrom, K. Tsaparikos, D. J. Shields, D. D. Fang, M. E. Lira, Z. Zhu, M. D. Robbins, R. Schwab, M. J. Munchhof and T. VanArsdale, Abstract 4504: PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models, Exp. Mol. Ther. (pp. 4504–4504). Presented at the Proceedings: AACR 102nd Annual Meeting 2011 - Apr 2-6, 2011; Orlando, FL, American Association for Cancer Research; https://doi.org/10.1158/1538-7445.AM2011-450410.1158/1538-7445.AM2011-4504
]Search in Google Scholar
[
35. G. Martinelli, V. G. Oehler, C. Papayannidis, R. Courtney, M. N. Shaik, X. Zhang, A. O’Connell, K. R. McLachlan, X. Zheng, J. Radich, M. Baccarani, H. M. Kantarjian, W. J. Levin, J. E. Cortes and C. Jamieson, Treatment with PF-04449913, an oral Smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study, Lancet Haematol. 2 (2015) e339-346; https://doi.org/10.1016/S2352-3026(15)00096-410.1016/S2352-3026(15)00096-4
]Search in Google Scholar
[
36. A. J. Wagner, W. A. Messersmith, M. N. Shaik, S. Li, X. Zheng, K. R. McLachlan, R. Cesari, R. Courtney, W. J. Levin and A. B. El-Khoueiry, A phase I study of PF-04449913, an oral Hedgehog inhibitor, in patients with advanced solid tumors, Clin. Cancer Res. 21 (2015) 1044–1051; https://doi.org/10.1158/1078-0432.CCR-14-111610.1158/1078-0432.CCR-14-111625388167
]Search in Google Scholar
[
37. G. Giordani, M. Barraco, A. Giangrande, G. Martinelli, V. Guadagnuolo, G. Simonetti, G. Perini and R. Bernardoni, The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells, Oncotarget 7 (2016) 55313–55327; https://doi.org/10.18632/oncotarget.1087910.18632/oncotarget.10879534241927486815
]Search in Google Scholar
[
38. M. Copland, A. Hamilton, L. J. Elrick, J. W. Baird, E. K. Allan, N. Jordanides, M. Barow, J. C. Mountford and T. L. Holyoake, Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction, Blood 107 (2006) 4532–4539; https://doi.org/10.1182/blood-2005-07-294710.1182/blood-2005-07-294716469872
]Search in Google Scholar
[
39. X. Jiang, Y. Zhao, C. Smith, M. Gasparetto, A. Turhan, A. Eaves and C. Eaves, Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies, Leukemia 21 (2007) 926–935; https://doi.org/10.1038/sj.leu.240460910.1038/sj.leu.240460917330101
]Search in Google Scholar
[
40. C. Dierks, R. Beigi, G.-R. Guo, K. Zirlik, M. R. Stegert, P. Manley, C. Trussell, A. Schmitt-Graeff, K. Landwerlin, H. Veelken and M. Warmuth, Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation, Cancer Cell 14 (2008) 238–249; https://doi.org/10.1016/j.ccr.2008.08.00310.1016/j.ccr.2008.08.00318772113
]Search in Google Scholar
[
41. N. Fukushima, Y. Minami, S. Kakiuchi, Y. Kuwatsuka, F. Hayakawa, C. Jamieson, H. Kiyoi and T. Naoe, Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells, Cancer Sci. 107 (2016) 1422–1429; https://doi.org/10.1111/cas.1301910.1111/cas.13019508466427461445
]Search in Google Scholar
[
42. A. Schairer, A. Shih, I. Geron, T. Reya, W. J. Levin, T. Van Arsdale and C. Jamieson, Human blast crisis leukemia stem cell inhibition with a novel Smoothened antagonist., Blood 116 (2010) 1223–1223; https://doi.org/10.1182/blood.V116.21.1223.122310.1182/blood.V116.21.1223.1223
]Search in Google Scholar
[
43. A. Y. Shih, A. Schairer, C. L. Barrett, I. Geron, A. C. Court Recart, D. Goff, S. Prashad, J. Wu, Q. Jiang, J. Gotlib, L. Balaian, M. D. Minden, H. Leu, R. Wall, W. Ma, K. Shazand, J. D. McPherson, S. M. Kornblau, I. Deichaite, M. Pu, L. Bao, G. Martinelli, T. Reya, S. R. Morris, T. van Arsdale, T. J. Hudson, K. Messer, H. Mikkola, W. J. Levin, K. A. Frazer, A. Sadarangani and C. Jamieson, Cycling toward leukemia stem cell elimination with a selective Sonic Hedgehog antagonist, Blood 118 (2011) 3776–3776; https://doi.org/10.1182/blood.V118.21.3776.377610.1182/blood.V118.21.3776.3776
]Search in Google Scholar
[
44. P. Chaudhry, M. Singh, T. J. Triche, M. Guzman and A. A. Merchant, GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML, Blood 129 (2017) 3465–3475; https://doi.org/10.1182/blood-2016-05-71858510.1182/blood-2016-05-718585549208928487292
]Search in Google Scholar
[
45. A. Jackson-Fisher, P. Whalen, M. Elliott, M. McMahon, E. Chen, X. Zheng, M. Ozeck, D. Huang, P. Lira, J. Lee, C. Zhang, J. Lam, M. Spilker, S. Deng, P. Lappin, P. Venne, C. Heinlein, A. Schairer, K. McLachlan and T. VanArsdale, Abstract 1958: Interrogating Hedgehog pathway and smoothened inhibition by PF-04449913 in patient-derived acute myeloid leukemia models, Tumor Biol. (pp. 1958–1958). Presented at the Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA, American Association for Cancer Research; https://doi.org/10.1158/1538-7445.AM2014-195810.1158/1538-7445.AM2014-1958
]Search in Google Scholar
[
46. A. Sadarangani, G. Pineda, K. M. Lennon, H.-J. Chun, A. Shih, A. E. Schairer, A. C. Court, D. J. Goff, S. L. Prashad, I. Geron, R. Wall, J. D. McPherson, R. A. Moore, M. Pu, L. Bao, A. Jackson-Fisher, M. Munchhof, T. VanArsdale, T. Reya, S. R. Morris, M. D. Minden, K. Messer, H. K. A. Mikkola, M. A. Marra, T. J. Hudson and C. H. M. Jamieson, GLI2 inhibition abrogates human leukemia stem cell dormancy, J. Transl. Med. 13 (2015) 98; https://doi.org/10.1186/s12967-015-0453-910.1186/s12967-015-0453-9441437525889765
]Search in Google Scholar
[
47. C. Jamieson, J. E. Cortes, V. Oehler, M. Baccarani, H. M. Kantarjian, C. Papayannidis, K. N. Rice, X. Zhang, N. Shaik, R. Courtney, W. J. Levin and G. Martinelli, Phase 1 Dose-escalation study of PF-04449913, an oral Hedgehog (Hh) inhibitor, in patients with select hematologic malignancies, Blood 118 (2011) 424–424; https://doi.org/10.1182/blood.V118.21.424.42410.1182/blood.V118.21.424.424
]Search in Google Scholar
[
48. V. Guadagnuolo, C. Papayannidis, I. Iacobucci, S. Durante, C. Terragna, E. Ottaviani, M. C. Abbenante, F. Cattina, S. Soverini, B. Lama, L. Toni, W. J. Levin, R. Courtney, C. Baldazzi, A. Curti, M. Baccarani, C. Jamieson, J. E. Cortes, V. Oehler, K. McLachlan, T. Van Arsdale and G. Martinelli, Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients, Blood 118 (2011) 1535–1535; https://doi.org/10.1182/blood.V118.21.1535.153510.1182/blood.V118.21.1535.1535
]Search in Google Scholar
[
49. C. Papayannidis, V. Guadagnuolo, I. Iacobucci, S. Durante, C. Terragna, E. Ottaviani, M. C. Abbenante, F. Cattina, S. Soverini, B. Lama, L. Toni, W. J. Levin, R. Courtney, C. Baldazzi, A. Curti, M. Baccarani, C. Jamieson, J. E. Cortes, V. Oehler, K. McLachlan, T. Van Arsdale and G. Martinelli, PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients, Blood 118 (2011) 1429–1429; https://doi.org/10.1182/blood.V118.21.1429.142910.1182/blood.V118.21.1429.1429
]Search in Google Scholar
[
50. Y. Minami, H. Minami, T. Miyamoto, G. Yoshimoto, Y. Kobayashi, W. Munakata, Y. Onishi, M. Kobayashi, M. Ikuta, G. Chan, A. Woolfson, C. Ono, M. N. Shaik, Y. Fujii, X. Zheng and T. Naoe, Phase I study of glasdegib (PF-04449913), an oral Smoothened inhibitor, in Japanese patients with select hematologic malignancies, Cancer Sci. 108 (2017) 1628–1633; https://doi.org/10.1111/cas.1328510.1111/cas.13285554350728556364
]Search in Google Scholar
[
51. M. R. Savona, D. A. Pollyea, W. Stock, V. G. Oehler, M. A. Schroeder, J. Lancet, J. McCloskey, H. M. Kantarjian, W. W. Ma, M. N. Shaik, A. D. Laird, M. Zeremski, A. O’Connell, G. Chan and J. E. Cortes, Phase Ib study of glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS, Clin. Cancer Res. 24 (2018) 2294–2303; https://doi.org/10.1158/1078-0432.CCR-17-282410.1158/1078-0432.CCR-17-282429463550
]Search in Google Scholar
[
52. U. Borate, B. D. Smith, S. Gore, A. M. Zeidan, M. R. Savona, M. L. Savoie, N. Zhu, D. Breems, X. Zhang, M. N. Shaik, A. Rampersad, G. Chan, A. Woolfson and M. A. Sekeres, Phase 1B study of glasdegib (PF-04449913) in combination with azacitidine in patients with higher risk myelodysplasic syndrome, oligoblastic acute myeloid leukemia, or chronic myelomonocytic leukemia [abstract no. P255], Haematologica 101 (Suppl 1) (2016) 73–74.
]Search in Google Scholar
[
53. M. A. Sekeres, M. W. Schuster, M. Joris, J. Krauter, J. A. Maertens, E. Gyan, T. Kovacsovics, A. Verma, P. Vyas, E. S. Wang, W. Wendy Ma, M. Zeremski, A. Kudla, G. Chan and A. M. Zeidan, A phase 1b study of glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia, Blood 134 (2019) 177–177; https://doi.org/10.1182/blood-2019-12405010.1182/blood-2019-124050
]Search in Google Scholar
[
54. A. M. Zeidan, M. Schuster, M. Joris, J. Krauter, J. Maertens, E. Gyan, T. Kovacsovics, A. Verma, P. Vyas, E. S. Wang, W. Ma, M. Zeremski, A. Kudla, G. Chan and M. A. Sekeres, Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence, J. Clin. Oncol. 38 (2020) 7526–7526; https://doi.org/10.1200/JCO.2020.38.15_suppl.752610.1200/JCO.2020.38.15_suppl.7526
]Search in Google Scholar
[
55. E. S. Wang, T. Bell, A. M. Zeidan, H. Bhattacharyya, A. Kudla, G. Chan and M. A. Sekeres, Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib + azacitidine (AZA), J. Clin. Oncol. 38 (2020) 7527–7527; https://doi.org/10.1200/JCO.2020.38.15_suppl.752710.1200/JCO.2020.38.15_suppl.7527
]Search in Google Scholar
[
56. A. T. Gerds, T. Tauchi, E. Ritchie, M. Deininger, C. Jamieson, R. Mesa, M. Heaney, N. Komatsu, H. Minami, Y. Su, N. Shaik, X. Zhang, C. DiRienzo, M. Zeremski, G. Chan and M. Talpaz, Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib, Leuk. Res. 79 (2019) 38–44; https://doi.org/10.1016/j.leukres.2019.02.01210.1016/j.leukres.2019.02.012814898530849661
]Search in Google Scholar
[
57. J. E. Cortes, B. Douglas Smith, E. S. Wang, A. Merchant, V. G. Oehler, M. Arellano, D. J. DeAngelo, D. A. Pollyea, M. A. Sekeres, T. Robak, W. W. Ma, M. Zeremski, M. Naveed Shaik, A. Douglas Laird, A. O’Connell, G. Chan and M. A. Schroeder, Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results, Am. J. Hematol. 93 (2018) 1301–1310; https://doi.org/10.1002/ajh.2523810.1002/ajh.25238622110230074259
]Search in Google Scholar
[
58. H. Kantarjian, Y. Oki, G. Garcia-Manero, X. Huang, S. O’Brien, J. Cortes, S. Faderl, C. Bueso-Ramos, F. Ravandi, Z. Estrov, A. Ferrajoli, W. Wierda, J. Shan, J. Davis, F. Giles, H. I. Saba and J.-P. J. Issa, Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, Blood 109 (2007) 52–57; https://doi.org/10.1182/blood-2006-05-02116210.1182/blood-2006-05-02116216882708
]Search in Google Scholar
[
59. S. Thépot, R. Itzykson, V. Seegers, C. Recher, E. Raffoux, B. Quesnel, J. Delaunay, T. Cluzeau, A. Marfaing Koka, A. Stamatoullas, M.-P. Chaury, C. Dartigeas, S. Cheze, A. Banos, P. Morel, I. Plan-tier, A.-L. Taksin, J. P. Marolleau, C. Pautas, X. Thomas, F. Isnard, B. Beve, Y. Chait, A. Guerci, N. Vey, F. Dreyfus, L. Ades, N. Ifrah, H. Dombret, P. Fenaux and C. Gardin, Azacitidine in untreated acute myeloid leukemia: a report on 149 patients: azacitidine in frontline AML, Am. J. Hematol. 89 (2014) 410–416; https://doi.org/10.1002/ajh.2365410.1002/ajh.2365424375487
]Search in Google Scholar
[
60. H. Dombret, J. F. Seymour, A. Butrym, A. Wierzbowska, D. Selleslag, J. H. Jang, R. Kumar, J. Cavenagh, A. C. Schuh, A. Candoni, C. Récher, I. Sandhu, T. Bernal del Castillo, H. K. Al-Ali, G. Martinelli, J. Falantes, R. Noppeney, R. M. Stone, M. D. Minden, H. McIntyre, S. Songer, L. M. Lucy, C. L. Beach and H. Döhner, International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts, Blood 126 (2015) 291–299; https://doi.org/10.1182/blood-2015-01-62166410.1182/blood-2015-01-621664450494525987659
]Search in Google Scholar
[
61. S. M. Luger, Acute myeloid leukemia: how to treat the fit patient over age 75?, Best Pract. Res. Clin. Haematol. 32 (2019) 101105; https://doi.org/10.1016/j.beha.2019.10110510.1016/j.beha.2019.10110531779985
]Search in Google Scholar
[
62. J. E. Cortes, A. Merchant, C. Jamieson, D. A. Pollyea, M. Heuser, G. Chan, P. Wang, K. A. Ching, J. Johnson and T. O’Brien, Biomarkers of overall survival and response to glasdegib and intensive or non-intensive chemotherapy in patients with acute myeloid leukemia, Blood 132 (2018) 1429–1429; https://doi.org/10.1182/blood-2018-99-11123910.1182/blood-2018-99-111239
]Search in Google Scholar
[
63. K. A. Ching, D. Huang, K. Wang, M. Ozeck, P. Lira, J. Gao, J. Bienkowska, P. Rejto, J. Hardwick, T. O’Brien and G. Chan, Analysis of mutations associated with response to glasdegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), Clin. Res. Clin. Trials (pp. LB-215–LB-215). Presented at the Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL, American Association for Cancer Research.; https://doi.org/10.1158/1538-7445.AM2018-LB-21510.1158/1538-7445.AM2018-LB-215
]Search in Google Scholar
[
64. S. Lin, N. Shaik, G. Chan, J. E. Cortes and A. Ruiz-Garcia, An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure, Cancer Chemother. Pharmacol. 86 (2020) 451–459; https://doi.org/10.1007/s00280-020-04132-x10.1007/s00280-020-04132-x
]Search in Google Scholar
[
65. H. Döhner, M. Lübbert, W. Fiedler, L. Fouillard, A. Haaland, J. M. Brandwein, S. Lepretre, O. Reman, P. Turlure, O. G. Ottmann, C. Müller-Tidow, A. Krämer, E. Raffoux, K. Döhner, R. F. Schlenk, F. Voss, T. Taube, H. Fritsch and J. Maertens, Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy, Blood 124 (2014) 1426–1433.; https://doi.org/10.1182/blood-2014-03-56055710.1182/blood-2014-03-560557
]Search in Google Scholar
[
66. A. K. Burnett, N. Russell, R. K. Hills, N. Panoskaltsis, A. Khwaja, C. Hemmaway, P. Cahalin, R. E. Clark and D. Milligan, A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia, Leukemia 29 (2015) 1312–1319; https://doi.org/10.1038/leu.2015.3810.1038/leu.2015.38
]Search in Google Scholar
[
67. M. Heiblig, M. Elhamri, I. Tigaud, A. Plesa, F. Barraco, H. Labussière, S. Ducastelle, M. Michallet, F. Nicolini, C. Plesa, E. Wattel, G. Salles and X. Thomas, Treatment with low-dose cytarabine in elderly patients (age 70 years or older) with acute myeloid leukemia: a single institution experience, Mediterr. J. Hematol. Infect. Dis. 8 (2016) 2016009; https://doi.org/10.4084/mjhid.2016.00910.4084/mjhid.2016.009
]Search in Google Scholar
[
68. A. T. Fathi, Glasdegib with low-dose cytarabine: a new upfront option for the vulnerable AML patient, Clin. Cancer Res. 25 (2019) 6015–6017; https://doi.org/10.1158/1078-0432.CCR-19-198610.1158/1078-0432.CCR-19-1986
]Search in Google Scholar
[
69. C. Papayannidis, B. D. Smith, M. Heuser, P. Montesinos, M. A. Sekeres, A. Oriol, G. Schiller, A. Candoni, C. Jamieson, C. J. Hoang, W. W. Ma, M. Zeremski, A. O’Connell, G. Chan and J. E. Cortes, Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: long-term analysis of a phase 2 randomized trial, Clin. Lymphoma Myeloma Leuk. 19 (2019) S228–S229; https://doi.org/10.1016/j.clml.2019.07.11110.1016/j.clml.2019.07.111
]Search in Google Scholar
[
70. M. Heuser, W. Fiedler, M. A. Sekeres, P. Montesinos, B. Leber, A. Merchant, C. Papayannidis, J. A. Pérez-Simón, C. J. Hoang, W. Wendy Ma, M. Zeremski, A. O’Connell, G. Chan and J. E. Cortes, Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase 2 randomized trial, Clin. Lymphoma Myeloma Leuk. 19 (2019) S231–S231; https://doi.org/10.1016/j.clml.2019.07.11610.1016/j.clml.2019.07.116
]Search in Google Scholar
[
71. C. D. DiNardo, K. W. Pratz, A. Letai, B. A. Jonas, A. H. Wei, M. Thirman, M. Arellano, M. G. Frattini, H. Kantarjian, R. Popovic, B. Chyla, T. Xu, M. Dunbar, S. K. Agarwal, R. Humerickhouse, M. Mabry, J. Potluri, M. Konopleva and D. A. Pollyea, Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study, Lancet Oncol. 19 (2018) 216–228; https://doi.org/10.1016/S1470-2045(18)30010-X10.1016/S1470-2045(18)30010-X
]Search in Google Scholar
[
72. A. Wolska-Washer and T. Robak, Glasdegib in the treatment of acute myeloid leukemia, Future Oncol. Lond. Engl. 15 (2019) 3219–3232; https://doi.org/10.2217/fon-2019-017110.2217/fon-2019-017131432695
]Search in Google Scholar
[
73. M. Heuser, T. Robak, P. Montesinos, B. Leber, W. M. Fiedler, D. A. Pollyea, A. Brown, A. O’Connell, W. Ma, G. Chan and J. E. Cortes, Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up, J. Clin. Oncol. 38 (2020) 7509–7509; https://doi.org/10.1200/JCO.2020.38.15_suppl.750910.1200/JCO.2020.38.15_suppl.7509
]Search in Google Scholar
[
74. J. E. Cortes, F. H. Heidel, W. Fiedler, B. D. Smith, T. Robak, P. Montesinos, A. Candoni, B. Leber, M. A. Sekeres, D. A. Pollyea, R. Ferdinand, W. W. Ma, T. O’Brien, A. O’Connell, G. Chan and M. Heuser, Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy, J. Hematol. Oncol. 13 (2020) 92; https://doi.org/10.1186/s13045-020-00929-810.1186/s13045-020-00929-8736256332664995
]Search in Google Scholar
[
75. E. S. Wang, M. Heuser, M. A. Sekeres, C. Papayannidis, A. Candoni, A. Merchant, A. Brown, A. O’Connell, W. Ma, G. Chan and J. E. Cortes, Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis, J. Clin. Oncol. 38 (2020) 7525–7525; https://doi.org/10.1200/JCO.2020.38.15_suppl.752510.1200/JCO.2020.38.15_suppl.7525
]Search in Google Scholar
[
76. G. Tremblay, T. Westley, J. C. Cappelleri, B. Arondekar, G. Chan, T. J. Bell and A. Briggs, Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons, Clin. Outcomes Res. CEOR 11 (2019) 551–565; https://doi.org/10.2147/CEOR.S20348210.2147/CEOR.S203482673565331564931
]Search in Google Scholar
[
77. S. van Beekhuizen, Y. Hu, A. Gezin, B. Heeg, T. Bell, M. Charaan, A. Brown, G. Chan and J. C. Cappelleri, The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy, J. Clin. Oncol. 38 (2020) e19512–e19512; https://doi.org/10.1200/JCO.2020.38.15_suppl.e1951210.1200/JCO.2020.38.15_suppl.e19512
]Search in Google Scholar
[
78. J. E. Lancet, R. S. Komrokji, K. L. Sweet, V. H. Duong, K. L. McGraw, L. Zhang, L. A. Nardelli, Z. Ma, R. R. Reich, E. Padron and A. F. List, Phase 2 trial of Smoothened (SMO) inhibitor PF-04449913 (PF-04) in refractory myelodysplastic syndromes (MDS), Blood 128 (2016) 3174–3174; https://doi.org/10.1182/blood.V128.22.3174.317410.1182/blood.V128.22.3174.3174
]Search in Google Scholar
[
79. D. A. Sallman, R. S. Komrokji, K. L. Sweet, Q. Mo, K. L. McGraw, V. H. Duong, L. Zhang, L. A. Nardelli, E. Padron, A. F. List and J. E. Lancet, A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS), Leuk. Res. 81 (2019) 56–61; https://doi.org/10.1016/j.leukres.2019.03.00810.1016/j.leukres.2019.03.008778734931030089
]Search in Google Scholar
[
80. A. M. Zeidan, M. W. Schuster, J. Krauter, J. A. Maertens, E. Gyan, M. Joris, T. F. Menne, P. Vyas, W. W. Ma, A. O’Connell, M. Zeremski, A. Kudla, G. Chan and M. A. Sekeres, Clinical benefit of glasdegib in combination with azacitidine or low-dose cytarabine in patients with acute myeloid leukemia, Blood 134 (2019) 3916–3916; https://doi.org/10.1182/blood-2019-12403410.1182/blood-2019-124034
]Search in Google Scholar
[
81. A. Kent, S. Vasu, D. Schatz, N. Monson, S. Devine, C. Smith, J. A. Gutman and D. A. Pollyea, Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postal-logeneic stem cell transplant relapse, Blood Adv. 4 (2020) 3102–3108; https://doi.org/10.1182/bloodadvances.202000199110.1182/bloodadvances.2020001991736234832634235
]Search in Google Scholar
[
82. J. E. Cortes, H. Dombret, A. A. Merchant, T. Tauchi, C. DiRienzo, M. Zeremski, B. Sleight, X. Zhang, M. N. Shaik, T. Bell, G. Chan and M. A. Sekeres, Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia, J. Clin. Oncol. 36 (2018) TPS7073–TPS7073; https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS707310.1200/JCO.2018.36.15_suppl.TPS7073
]Search in Google Scholar
[
83. J. E. Cortes, H. Dombret, A. Merchant, T. Tauchi, C. G. DiRienzo, B. Sleight, X. Zhang, E. P. Leip, N. Shaik, T. Bell, G. Chan and M. A. Sekeres, Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials, Future Oncol. 15 (2019) 3531–3545; https://doi.org/10.2217/fon-2019-037310.2217/fon-2019-037331516032
]Search in Google Scholar
[
84. S. Lin, M. Shaik and A. Ruiz, Population pharmacokinetics of glasdegib in patients with advanced hematologic and solid tumors (in “American Society for Clinical Pharmacology and Therapeutics - Abstracts of 2018 Annual Meeting”), Clin. Pharmacol. Ther. 103 (Suppl 1) (2018) S78; https://doi.org/10.1002/cpt.99310.1002/cpt.993
]Search in Google Scholar
[
85. S. Lin, N. Shaik, G. Martinelli, A. J. Wagner, J. Cortes and A. Ruiz-Garcia, Population pharmacokinetics of glasdegib in patients with advanced hematologic malignancies and solid tumors, J. Clin. Pharmacol. (2019); https://doi.org/10.1002/jcph.155610.1002/jcph.1556718737231769065
]Search in Google Scholar
[
86. N. Shaik, B. Hee, Y. Liang and R. R. LaBadie, Absolute oral bioavailability of glasdegib (PF-04449913), a Smoothened inhibitor, in randomized healthy volunteers, Clin. Pharmacol. Drug Dev. 8 (2019) 895–902; https://doi.org/10.1002/cpdd.69210.1002/cpdd.692685040330977980
]Search in Google Scholar
[
87. N. Giri, L. H. Lam, R. R. LaBadie, J. F. Krzyzaniak, H. Jiang, B. Hee, Y. Liang and M. N. Shaik, Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bio-availability of the Smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers, Cancer Chemother. Pharmacol. 80 (2017) 1249–1260; https://doi.org/10.1007/s00280-017-3472-910.1007/s00280-017-3472-929086063
]Search in Google Scholar
[
88. N. Shaik, B. Hee, H. Wei and R. R. LaBadie, Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study, Cancer Chemother. Pharmacol. 83 (2019) 463–472; https://doi.org/10.1007/s00280-018-3748-810.1007/s00280-018-3748-8639447430536154
]Search in Google Scholar
[
89. J. L. Lam, A. Vaz, B. Hee, Y. Liang, X. Yang and M. N. Shaik, Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration, Xenobiotica Fate Foreign Compd. Biol. Syst. 47 (2017) 1064–1076; https://doi.org/10.1080/00498254.2016.126130710.1080/00498254.2016.126130727866461
]Search in Google Scholar
[
90. M. N. Shaik, R. R. LaBadie, D. Rudin and W. J. Levin, Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the Smoothened inhibitor PF-04449913 in healthy volunteers, Cancer Chemother. Pharmacol. 74 (2014) 411–418; https://doi.org/10.1007/s00280-014-2502-010.1007/s00280-014-2502-024944041
]Search in Google Scholar
[
91. European Medicines Agency, Glasdegib (DAURISMO): EPAR - Product Information, https://www.ema.europa.eu/en/documents/product-information/daurismo-epar-product-information_en.pdf (accessed 10 October 2020).
]Search in Google Scholar
[
92. M. N. Shaik, B. Hee, H. Wei and R. R. LaBadie, Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers, Br. J. Clin. Pharmacol. 84 (2018) 1346–1353; https://doi.org/10.1111/bcp.1356810.1111/bcp.13568598054129488303
]Search in Google Scholar
[
93. A. Ruiz-Garcia, N. Shaik, S. Lin, C. Jamieson, M. Heuser and G. Chan, Evaluation of the relationship of glasdegib exposure and safety end points in patients with refractory solid tumors and hematologic malignancies, J. Clin. Pharmacol. (2020) jcph.1742; https://doi.org/10.1002/jcph.174210.1002/jcph.1742789144132974950
]Search in Google Scholar
[
94. M. Tavares, S. Chacim and J. M. Mariz, Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome, Ann. Hematol. (2020); https://doi.org/10.1007/s00277-020-04291-010.1007/s00277-020-04291-033001280
]Search in Google Scholar
[
95. N. Shaik, L. Mendes da Costa, B. Hee, Y. Liang and R. R. LaBadie, A thorough QT study to evaluate the effect of glasdegib on cardiac repolarization in healthy adult subjects (in “Abstracts for the Ninth American Conference on Pharmacometrics (ACoP9)”), J. Pharmacokinet. Pharmacodyn. 45 (2018) S87 [Abstract no. T-092]; https://doi.org/10.1007/s10928-018-9606-910.1007/s10928-018-9606-930203256
]Search in Google Scholar
[
96. J. C. Masters, N. Shaik, L. Mendes da Costa, B. Hee and R. R. LaBadie, Clinical and model-based evaluation of the effect of glasdegib on cardiac repolarization from a randomized thorough QT study, Clin. Pharmacol. Drug Dev. (2020) cpdd.862; https://doi.org/10.1002/cpdd.86210.1002/cpdd.862798388832790066
]Search in Google Scholar
[
97. N. Sarapa and M. R. Britto, Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents, Expert Opin. Drug Saf. 7 (2008) 305–318; https://doi.org/10.1517/14740338.7.3.30510.1517/14740338.7.3.30518462188
]Search in Google Scholar
[
98. E. Park, J. Willard, D. Bi, M. Fiszman, D. Kozeli and J. Koerner, The impact of drug-related QT prolongation on FDA regulatory decisions, Int. J. Cardiol. 168 (2013) 4975–4976; https://doi.org/10.1016/j.ijcard.2013.07.13610.1016/j.ijcard.2013.07.13623920061
]Search in Google Scholar
[
99. R. J. Lipinski, P. R. Hutson, P. W. Hannam, R. J. Nydza, I. M. Washington, R. W. Moore, G. G. Girdaukas, R. E. Peterson and W. Bushman, Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse, Toxicol. Sci. 104 (2008) 189–197; https://doi.org/10.1093/toxsci/kfn07610.1093/toxsci/kfn076292786818411234
]Search in Google Scholar
[
100. E. Morinello, M. Pignatello, L. Villabruna, P. Goelzer and H. Bürgin, Embryofetal development study of vismodegib, a Hedgehog pathway inhibitor, in rats, Birth Defects Res. B. Dev. Reprod. Toxicol. 101 (2014) 135–143; https://doi.org/10.1002/bdrb.2109310.1002/bdrb.2109324692404
]Search in Google Scholar
[
101. Glasdegib, Drugs Lact. Database Lact. Bethesda (MD): National Library of Medicine (US); Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK535600/
]Search in Google Scholar
[
102. S. V. Mohan and A. L. S. Chang, Management of cutaneous and extracutaneous side effects of smoothened inhibitor therapy for advanced basal cell carcinoma, Clin. Cancer Res. 21 (2015) 2677–2683; https://doi.org/10.1158/1078-0432.CCR-14-318010.1158/1078-0432.CCR-14-318025792568
]Search in Google Scholar
[
103. M. E. Lacouture, B. Dréno, P. A. Ascierto, R. Dummer, N. Basset-Seguin, K. Fife, S. Ernst, L. Licitra, R. I. Neves, K. Peris, S. Puig, J. Sokolof, A. Sekulic, A. Hauschild and R. Kunstfeld, Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma, The Oncologist 21 (2016) 1218–1229; https://doi.org/10.1634/theoncologist.2016-018610.1634/theoncologist.2016-0186506153227511905
]Search in Google Scholar
[
104. A. A. Jacobsen, A. R. Kydd and J. Strasswimmer, Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma, J. Am. Acad. Dermatol. 76 (2017) 767–768; https://doi.org/10.1016/j.jaad.2016.04.06310.1016/j.jaad.2016.04.06328325399
]Search in Google Scholar
[
105. X. Song, Y. Peng, X. Wang, Y. Chen, L. Jin, T. Yang, M. Qian, W. Ni, X. Tong and J. Lan, Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the surveillance, epidemiology, and end results (SEER) database, 2001–2013, Acta Haematol. 139 (2018) 115–127; https://doi.org/10.1159/00048622810.1159/00048622829455198
]Search in Google Scholar
[
106. German-Austrian AML Study Group (AMLSG), G. Nagel, D. Weber, E. Fromm, S. Erhardt, M. Lübbert, W. Fiedler, T. Kindler, J. Krauter, P. Brossart, A. Kündgen, H. R. Salih, J. Westermann, G. Wulf, B. Hertenstein, M. Wattad, K. Götze, D. Kraemer, T. Heinicke, M. Girschikofsky, H. G. Derigs, H. A. Horst, C. Rudolph, M. Heuser, G. Göhring, V. Teleanu, L. Bullinger, F. Thol, V. I. Gaidzik, P. Paschka, K. Döhner, A. Ganser, H. Döhner, R. F. Schlenk and the German-Austrian AML Study Group (AMLSG), Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO), Ann. Hematol. 96 (2017) 1993–2003; https://doi.org/10.1007/s00277-017-3150-310.1007/s00277-017-3150-3569109129090343
]Search in Google Scholar
[
107. X. Thomas and M. Heiblig, An evaluation of glasdegib for the treatment of acute myelogenous leukemia, Expert Opin. Pharmacother. 21 (2020) 523–530; https://doi.org/10.1080/14656566.2020.171309410.1080/14656566.2020.171309432027196
]Search in Google Scholar
[
108. N. Daver, A. H. Wei, D. A. Pollyea, A. T. Fathi, P. Vyas and C. D. DiNardo, New directions for emerging therapies in acute myeloid leukemia: the next chapter, Blood Cancer J. 10 (2020) 107; https://doi.org/10.1038/s41408-020-00376-110.1038/s41408-020-00376-1759922533127875
]Search in Google Scholar
[
109. J. E. Cortes, A. Candoni, R. E. Clark, B. Leber, P. Montesinos, P. Vyas, A. M. Zeidan and M. Heuser, Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review, Leuk. Lymphoma (2020) 1–19; https://doi.org/10.1080/10428194.2020.181744510.1080/10428194.2020.181744532967493
]Search in Google Scholar
[
110. J. C. Masters, R. R. LaBadie, J. Salageanu, J. Li and N. Shail, Pharmacokinetics and safety of glasdegib in participants with moderate/severe hepatic impairment: a phase I, single-dose, matched case-control study, Clin. Pharmacol. Drug Dev. (2020); https://doi.org/10.1002/cpdd.897.10.1002/cpdd.897835930833356019
]Search in Google Scholar
[
111. N. Shaik, R. LaBadie, B. Hee and G. Chan, Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib, Clin. Pharmacol. Ther. 107 (2020) (S1) S69–S69 [Abstract no. PII-126]; https://doi.org/10.1002/cpt.173210.1002/cpt.173232060909
]Search in Google Scholar
[
112. H. A. Pham, S. Milev, S. Li, D. Zou, Y. Hu, B. Heeg and T. J. Bell, Budget impact of glasdegib in combination with low-dose cytarabine for the treatment of first-line acute myeloid leukemia in the United States, Blood 134 (2019) 5852–5852; https://doi.org/10.1182/blood-2019-12270910.1182/blood-2019-122709
]Search in Google Scholar
[
113. S. R. Goldsmith, A. R. Lovell and M. A. Schroeder, Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy, Drugs Today 55 (2019) 545; https://doi.org/10.1358/dot.2019.55.9.302016010.1358/dot.2019.55.9.302016031584572
]Search in Google Scholar
[
114. R. M. Shallis, N. A. Podoltsev, T. Prebet and A. M. Zeidan, Trial in progress: Glad-AML – a randomized, phase 2 trial of glasdegib with two standard decitabine regimens for older patients with newly-diagnosed, poor-risk acute myeloid leukemia, Blood 136 (2020) 29–29; https://doi.org/10.1182/blood-2020-13942810.1182/blood-2020-139428
]Search in Google Scholar